People | November 11, 2022
Biogen appoints Christopher Viehbacher as President and CEO
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The new program includes upstream and downstream process development and large-scale GMP production.
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
Subscribe To Our Newsletter & Stay Updated
